Last updated: May 29, 2026

Application No. 18/030,222

Mutant KRAS-Targeting Peptide and Use Thereof

Non-Final OA

Filed

Apr 04, 2023

Priority

Oct 08, 2020 — RE 10-2020-0130300 +1 more

Examiner

DEVI, SARVAMANGALA

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Gjmedi Inc.

OA Round

1 (Non-Final)

Interview Optional

— +55.0% interview lift. Examiner has a relatively high allowance rate (65%); +55.0% interview lift. A written response may suffice.

Based on 868 resolved cases, 2023–2026

Examiner Intelligence

DEVI, SARVAMANGALA View full profile →

Grants 65% — above average

Career Allowance Rate

568 granted / 868 resolved

+5.4% vs TC avg

Strong +55% interview lift

Without

With

+55.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

44 currently pending

Career history

919

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

28.8%

-11.2% vs TC avg

§102

25.4%

-14.6% vs TC avg

§112

25.8%

-14.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 868 resolved cases

Prosecution Timeline

Apr 04, 2023

Application Filed

Dec 23, 2025

Non-Final Rejection (signed)

Feb 02, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/570,332

Patent 12636322

BACTERIAL STRAIN WITH HIGH CELLULOLYTIC ACTIVITY

2y 5m to grant Granted May 26, 2026

18/768,336

Patent 12637495

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

1y 10m to grant Granted May 26, 2026

18/386,593

Patent 12629409

VACCINE

2y 6m to grant Granted May 19, 2026

17/626,866

Patent 12624093

EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS

4y 4m to grant Granted May 12, 2026

18/148,955

Patent 12616725

NOVEL BIFIDOBACTERIUM BREVE IDCC 4401 STRAIN AND ITS DEAD CELL ID-BBR4401 HAVING EXCELLENT ACID TOLERANCE AND BILE TOLERANCE AND PROPHYLACTIC OR THERAPEUTIC EFFECT ON DYSLIPIDEMIA

3y 4m to grant Granted May 05, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

65%

Grant Probability

99%

With Interview (+55.0%)

3y 4m (~2m remaining)

Median Time to Grant

Low

PTA Risk

Based on 868 resolved cases by this examiner. Grant probability derived from career allowance rate.